ATE365807T1 - Hepatitis b virus vektoren für gentherapie - Google Patents

Hepatitis b virus vektoren für gentherapie

Info

Publication number
ATE365807T1
ATE365807T1 AT01303622T AT01303622T ATE365807T1 AT E365807 T1 ATE365807 T1 AT E365807T1 AT 01303622 T AT01303622 T AT 01303622T AT 01303622 T AT01303622 T AT 01303622T AT E365807 T1 ATE365807 T1 AT E365807T1
Authority
AT
Austria
Prior art keywords
hepatitis
gene therapy
virus vectors
vivo
deliver therapeutic
Prior art date
Application number
AT01303622T
Other languages
English (en)
Inventor
Wang-Shick Ryu
Jehan Lee
Joog-Keun Jeong
Woo Young Cho
Gye Soon Yoon
Original Assignee
Wang-Shick Ryu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0019645A external-priority patent/KR100452718B1/ko
Application filed by Wang-Shick Ryu filed Critical Wang-Shick Ryu
Application granted granted Critical
Publication of ATE365807T1 publication Critical patent/ATE365807T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01303622T 2000-04-20 2001-04-20 Hepatitis b virus vektoren für gentherapie ATE365807T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000021070 2000-04-20
KR10-2001-0019645A KR100452718B1 (ko) 2000-04-20 2001-04-12 유전자 치료용 재조합 ｂ형 간염 바이러스 플라스미드 벡터

Publications (1)

Publication Number Publication Date
ATE365807T1 true ATE365807T1 (de) 2007-07-15

Family

ID=26637882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01303622T ATE365807T1 (de) 2000-04-20 2001-04-20 Hepatitis b virus vektoren für gentherapie

Country Status (5)

Country Link
US (1) US7001760B2 (de)
EP (1) EP1149917B1 (de)
JP (1) JP3621355B2 (de)
AT (1) ATE365807T1 (de)
DE (1) DE60129069D1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7015317B2 (en) * 2002-05-02 2006-03-21 Abbott Laboratories Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids
US20080096839A1 (en) * 2005-03-09 2008-04-24 Mogam Biotechnology Research Institute Small Interfering Rna and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
EP2198020B1 (de) * 2007-09-14 2016-04-13 Institut Pasteur Die expression und sekretion von fremdepitope enthaltendem rekombinantem pseudovirus gestattende polynukleotide, deren herstellung und verwendung
CN103402546B (zh) 2011-02-10 2018-04-13 海德堡鲁普雷希特卡尔斯大学 用于肝特异性诊断的疏水性修饰肽
JP6486004B2 (ja) 2011-02-10 2019-03-20 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ 疎水性修飾ペプチドおよび肝臓特異的標的化のためのその使用
WO2015057919A1 (en) * 2013-10-18 2015-04-23 The Johns Hopkins University Transgenic hepatitis b virus (hbv): a new model of hbv infection identifies uqcr10 as a viral replication factor
EP3189850A1 (de) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Auf die leber gerichtete cyclische pres-peptide von hbv
CN114761566A (zh) * 2019-08-29 2022-07-15 G科技生物有限责任公司 用于治疗病毒感染的组合物和方法
CN111575316A (zh) * 2020-05-19 2020-08-25 东莞市松山湖中心医院(东莞市石龙人民医院、东莞市第三人民医院、东莞市心血管病研究所) hKLK1重组质粒、高表达hKLK1的慢病毒颗粒及其构建方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88257I2 (de) * 1978-12-22 1994-02-03
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
AU619753B2 (en) * 1987-06-22 1992-02-06 Medeva Holdings B.V. Hepatitis b surface antigen vaccine
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
GB9707221D0 (en) * 1997-04-09 1997-05-28 Univ Glasgow Hepatitis B virus mutations

Also Published As

Publication number Publication date
EP1149917B1 (de) 2007-06-27
EP1149917A3 (de) 2001-11-14
JP2002320480A (ja) 2002-11-05
EP1149917A2 (de) 2001-10-31
US20010049145A1 (en) 2001-12-06
DE60129069D1 (de) 2007-08-09
US7001760B2 (en) 2006-02-21
JP3621355B2 (ja) 2005-02-16

Similar Documents

Publication Publication Date Title
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
TR201906106T4 (tr) Amiyotrofik lateral skleroz ve diğer omurilik hastalıkları için gen tedavisi.
DK1124846T3 (da) Nukleotid- og proteinsekvenser af Nogo-gener og derpå baserede fremgangsmåder
DK1916258T3 (da) Forøgelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar
ATE531808T1 (de) Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna
MX2009002816A (es) Proteinas de fusion de albumina.
FR11C0027I2 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
DK1240325T3 (da) IL-17 og IL-17R homologe polypeptider og terapeutisk anvendelse deraf
DE60142840D1 (de) Durch phagendisplay identifizierte zielpeptide des menschen und der maus
DK1516932T3 (da) Koppevirus med målrettet infektionsspecificitet
DK1677833T3 (da) Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
DE69932599D1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
ATE438727T1 (de) Optimierung von transgenexpression in säugetierzellen
DE60331758D1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
DE69930123D1 (de) Zielgerichtete integration in chromosomen mittels retroviraler vektoren
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
DK1761273T3 (da) Behandling af ikke-alkoholisk steatotisk hepatitis (NASH)
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
DE60002603D1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
DE60031539D1 (de) Mutiertes nurr1 gen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties